Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in COVID-19 with Acute Myocardial Injury
NCT04365153Phase 2Completed
- Sponsor
- Cleveland Clinic
- Start
- Apr 2020
- Primary completion
- Feb 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in coronavirus disease 2019 (COVID-19), sponsored by Cleveland Clinic. Started Apr 2020; status: completed.
02
Drugs
canakinumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04365153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04365153.